A study investigating the chemotherapeutic role of Bortezomib and its underlying mechanism in gliomas, revealed a connection between the effect of the proteasome inhibitor and the Akt/FoxM1 signaling axis. This evidence concerns the gene AKT1 and central nervous system cancer.